Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Moderate to Severe Atopic Dermatitis

NCT06727552 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT06727552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06727552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 18, 2024
Completion date
December 31, 2026
Enrollment
131 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis